Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC labeling reg

This article was originally published in The Tan Sheet

Executive Summary

FDA draft guidance on exemption/deferral applications based on insufficient labeling space is "meaningless in a practical sense" because "if it were possible or practicable to reconfigure or re-engineer the packaging to meet the final regulation, no exemption would be necessary," CHPA says in Feb. 20 comments. In a draft guidance published in December, FDA reiterates it will not routinely grant exemptions for products that claim to be too small to satisfy the final labeling reg requirements, but will consider deferral requests to allow packaging changes (1"The Tan Sheet" Jan. 1, p. 10). In separate comments, CTFA calls "vague and impracticable" FDA's proposed response times of 30-60 days for "straightforward requests" for exemption or deferral and 120-180 days for "new or complex issues"

You may also be interested in...



OTC Labeling Exemption, Deferral Timelines Depend On Complexity - FDA

FDA expects to respond to completed OTC labeling exemption and deferral requests that are straightforward or "consistent with previously granted requests" in 30 to 60 days, the agency says.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel